nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CYP3A4—bone cancer	0.545	1	CbGaD
Boceprevir—CTSK—Osteoclast Signaling—TNFRSF11A—bone cancer	0.0189	0.116	CbGpPWpGaD
Boceprevir—CTSK—periosteum—bone cancer	0.014	0.128	CbGeAlD
Boceprevir—CTSK—skull—bone cancer	0.0115	0.105	CbGeAlD
Boceprevir—CTSK—leg—bone cancer	0.0111	0.102	CbGeAlD
Boceprevir—CTSK—forelimb—bone cancer	0.011	0.102	CbGeAlD
Boceprevir—CTSK—hindlimb—bone cancer	0.00994	0.0914	CbGeAlD
Boceprevir—CTSK—cartilage tissue—bone cancer	0.00978	0.0899	CbGeAlD
Boceprevir—CTSK—appendage—bone cancer	0.00853	0.0784	CbGeAlD
Boceprevir—CTSK—RANKL/RANK Signaling Pathway—TNFRSF11A—bone cancer	0.00702	0.0433	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—PLOD2—bone cancer	0.00604	0.0372	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—PLOD2—bone cancer	0.00604	0.0372	CbGpPWpGaD
Boceprevir—CTSL—Assembly of collagen fibrils and other multimeric structures—LOX—bone cancer	0.00438	0.027	CbGpPWpGaD
Boceprevir—CTSV—Assembly of collagen fibrils and other multimeric structures—LOX—bone cancer	0.00438	0.027	CbGpPWpGaD
Boceprevir—Telaprevir—CYP3A4—bone cancer	0.00434	1	CrCbGaD
Boceprevir—CTSS—Collagen formation—PLOD2—bone cancer	0.00412	0.0254	CbGpPWpGaD
Boceprevir—CMA1—connective tissue—bone cancer	0.00378	0.0347	CbGeAlD
Boceprevir—CTSL—connective tissue—bone cancer	0.00323	0.0297	CbGeAlD
Boceprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—LOX—bone cancer	0.00299	0.0184	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—LOX—bone cancer	0.00298	0.0184	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—LOX—bone cancer	0.00298	0.0184	CbGpPWpGaD
Boceprevir—CTSL—Primary Focal Segmental Glomerulosclerosis FSGS—WT1—bone cancer	0.00297	0.0183	CbGpPWpGaD
Boceprevir—CTSV—spinal cord—bone cancer	0.00262	0.0241	CbGeAlD
Boceprevir—CMA1—bone marrow—bone cancer	0.00251	0.0231	CbGeAlD
Boceprevir—CTSK—connective tissue—bone cancer	0.00243	0.0224	CbGeAlD
Boceprevir—CTSV—Extracellular matrix organization—PLOD2—bone cancer	0.00242	0.0149	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—PLOD2—bone cancer	0.00242	0.0149	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—PLOD2—bone cancer	0.00225	0.0138	CbGpPWpGaD
Boceprevir—CTSL—tendon—bone cancer	0.00222	0.0204	CbGeAlD
Boceprevir—CTSL—bone marrow—bone cancer	0.00215	0.0198	CbGeAlD
Boceprevir—CTSL—spinal cord—bone cancer	0.00214	0.0197	CbGeAlD
Boceprevir—CTSS—connective tissue—bone cancer	0.00213	0.0196	CbGeAlD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.00208	0.0128	CbGpPWpGaD
Boceprevir—CTSS—Collagen formation—LOX—bone cancer	0.00204	0.0125	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—PLOD2—bone cancer	0.002	0.0123	CbGpPWpGaD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.00193	0.0119	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—IGF1R—bone cancer	0.00185	0.0114	CbGpPWpGaD
Boceprevir—CTSL—Collagen degradation—MMP2—bone cancer	0.00181	0.0111	CbGpPWpGaD
Boceprevir—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0018	0.0111	CbGpPWpGaD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.00172	0.0106	CbGpPWpGaD
Boceprevir—CTSK—tendon—bone cancer	0.00167	0.0154	CbGeAlD
Boceprevir—CTSS—Extracellular matrix organization—PLOD2—bone cancer	0.00165	0.0102	CbGpPWpGaD
Boceprevir—CTSK—bone marrow—bone cancer	0.00162	0.0149	CbGeAlD
Boceprevir—CTSK—spinal cord—bone cancer	0.00161	0.0148	CbGeAlD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP9—bone cancer	0.00156	0.00961	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—PLAU—bone cancer	0.00151	0.00932	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP2—bone cancer	0.0015	0.00923	CbGpPWpGaD
Boceprevir—CTSS—tendon—bone cancer	0.00147	0.0135	CbGeAlD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP9—bone cancer	0.00145	0.00894	CbGpPWpGaD
Boceprevir—CTSS—bone marrow—bone cancer	0.00142	0.0131	CbGeAlD
Boceprevir—CTSS—spinal cord—bone cancer	0.00141	0.013	CbGeAlD
Boceprevir—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00137	0.00843	CbGpPWpGaD
Boceprevir—CTSL—Collagen degradation—MMP9—bone cancer	0.00136	0.00838	CbGpPWpGaD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP9—bone cancer	0.00129	0.00796	CbGpPWpGaD
Boceprevir—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00128	0.0079	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00128	0.00788	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00126	0.00774	CbGpPWpGaD
Boceprevir—CTSV—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00126	0.00774	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—MOGS—bone cancer	0.00124	0.00761	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—LOX—bone cancer	0.00119	0.00736	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—LOX—bone cancer	0.00119	0.00736	CbGpPWpGaD
Boceprevir—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00116	0.00714	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP9—bone cancer	0.00113	0.00694	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—LOX—bone cancer	0.00111	0.00684	CbGpPWpGaD
Boceprevir—CTSV—Assembly of collagen fibrils and other multimeric structures—MMP9—bone cancer	0.00106	0.00652	CbGpPWpGaD
Boceprevir—CTSL—Assembly of collagen fibrils and other multimeric structures—MMP9—bone cancer	0.00106	0.00652	CbGpPWpGaD
Boceprevir—CTSK—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00104	0.00642	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—LOX—bone cancer	0.000989	0.0061	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP2—bone cancer	0.000915	0.00564	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP2—bone cancer	0.000915	0.00564	CbGpPWpGaD
Boceprevir—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000908	0.00559	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—MMP9—bone cancer	0.000896	0.00552	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—SPARC—bone cancer	0.000895	0.00551	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—SPARC—bone cancer	0.000895	0.00551	CbGpPWpGaD
Boceprevir—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000871	0.00537	CbGpPWpGaD
Boceprevir—CTSK—RANKL/RANK Signaling Pathway—JUN—bone cancer	0.000861	0.00531	CbGpPWpGaD
Boceprevir—CTSS—Toll-Like Receptors Cascades—ATF1—bone cancer	0.000857	0.00528	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP2—bone cancer	0.000851	0.00524	CbGpPWpGaD
Boceprevir—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000839	0.00517	CbGpPWpGaD
Boceprevir—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000838	0.00516	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—SPARC—bone cancer	0.000832	0.00513	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—LOX—bone cancer	0.000815	0.00502	CbGpPWpGaD
Boceprevir—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000789	0.00486	CbGpPWpGaD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000777	0.00479	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP2—bone cancer	0.000759	0.00467	CbGpPWpGaD
Boceprevir—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000749	0.00461	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—SPARC—bone cancer	0.000741	0.00457	CbGpPWpGaD
Boceprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000736	0.00454	CbGpPWpGaD
Boceprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—MMP9—bone cancer	0.000722	0.00445	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—MMP9—bone cancer	0.000721	0.00444	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—MMP9—bone cancer	0.000721	0.00444	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP9—bone cancer	0.000688	0.00424	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP9—bone cancer	0.000688	0.00424	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—TUBB4B—bone cancer	0.000677	0.00417	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—KIT—bone cancer	0.000665	0.0041	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP9—bone cancer	0.00064	0.00394	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP2—bone cancer	0.000625	0.00385	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—SPARC—bone cancer	0.00061	0.00376	CbGpPWpGaD
Boceprevir—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000598	0.00369	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—TUBB2A—bone cancer	0.000584	0.0036	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP9—bone cancer	0.00057	0.00351	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—MDM2—bone cancer	0.000523	0.00323	CbGpPWpGaD
Boceprevir—CTSS—Collagen formation—MMP9—bone cancer	0.000492	0.00303	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—JUN—bone cancer	0.000489	0.00302	CbGpPWpGaD
Boceprevir—CTSV—Toll-Like Receptors Cascades—JUN—bone cancer	0.000489	0.00302	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP9—bone cancer	0.00047	0.00289	CbGpPWpGaD
Boceprevir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000453	0.00279	CbGpPWpGaD
Boceprevir—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000451	0.00278	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—MMP9—bone cancer	0.000443	0.00273	CbGpPWpGaD
Boceprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00043	0.00265	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—EIF2S1—bone cancer	0.000408	0.00251	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—ATF1—bone cancer	0.000407	0.00251	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—ATF1—bone cancer	0.000407	0.00251	CbGpPWpGaD
Boceprevir—CTSK—Toll-Like Receptors Cascades—JUN—bone cancer	0.000406	0.0025	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP2—bone cancer	0.000384	0.00236	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP2—bone cancer	0.000384	0.00236	CbGpPWpGaD
Boceprevir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000362	0.00223	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000361	0.00223	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—EGFR—bone cancer	0.000358	0.0022	CbGpPWpGaD
Boceprevir—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000357	0.0022	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP2—bone cancer	0.000357	0.0022	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—ATF1—bone cancer	0.000337	0.00208	CbGpPWpGaD
Boceprevir—CTSS—Toll-Like Receptors Cascades—JUN—bone cancer	0.000334	0.00206	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP2—bone cancer	0.000318	0.00196	CbGpPWpGaD
Boceprevir—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000293	0.00181	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP9—bone cancer	0.000288	0.00178	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP9—bone cancer	0.000288	0.00178	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—ATF1—bone cancer	0.000278	0.00171	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—RGS1—bone cancer	0.000274	0.00169	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—GRM4—bone cancer	0.000274	0.00169	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP9—bone cancer	0.000268	0.00165	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP2—bone cancer	0.000262	0.00161	CbGpPWpGaD
Boceprevir—ABCB1—bone marrow—bone cancer	0.00025	0.0023	CbGeAlD
Boceprevir—ABCB1—spinal cord—bone cancer	0.000249	0.00229	CbGeAlD
Boceprevir—CTSK—Extracellular matrix organization—MMP9—bone cancer	0.000239	0.00147	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—GRM1—bone cancer	0.000238	0.00147	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ATF1—bone cancer	0.000237	0.00146	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ATF1—bone cancer	0.000237	0.00146	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—KIT—bone cancer	0.000232	0.00143	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—KIT—bone cancer	0.000232	0.00143	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL3—bone cancer	0.000231	0.00142	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL3—bone cancer	0.000231	0.00142	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—KIT—bone cancer	0.000222	0.00137	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—KIT—bone cancer	0.000222	0.00137	CbGpPWpGaD
Boceprevir—Conjunctivitis—Epirubicin—bone cancer	0.000222	0.00124	CcSEcCtD
Boceprevir—Urinary tract infection—Epirubicin—bone cancer	0.000222	0.00124	CcSEcCtD
Boceprevir—Neutropenia—Doxorubicin—bone cancer	0.000221	0.00124	CcSEcCtD
Boceprevir—Dysuria—Doxorubicin—bone cancer	0.000221	0.00124	CcSEcCtD
Boceprevir—Pollakiuria—Doxorubicin—bone cancer	0.000219	0.00122	CcSEcCtD
Boceprevir—Pharyngitis—Methotrexate—bone cancer	0.000217	0.00121	CcSEcCtD
Boceprevir—Urinary tract disorder—Methotrexate—bone cancer	0.000216	0.00121	CcSEcCtD
Boceprevir—Photosensitivity reaction—Doxorubicin—bone cancer	0.000216	0.00121	CcSEcCtD
Boceprevir—Hepatobiliary disease—Epirubicin—bone cancer	0.000216	0.00121	CcSEcCtD
Boceprevir—Epistaxis—Epirubicin—bone cancer	0.000215	0.0012	CcSEcCtD
Boceprevir—Urethral disorder—Methotrexate—bone cancer	0.000215	0.0012	CcSEcCtD
Boceprevir—Weight decreased—Doxorubicin—bone cancer	0.000214	0.0012	CcSEcCtD
Boceprevir—Sinusitis—Epirubicin—bone cancer	0.000214	0.0012	CcSEcCtD
Boceprevir—Hyperglycaemia—Doxorubicin—bone cancer	0.000214	0.00119	CcSEcCtD
Boceprevir—Agranulocytosis—Epirubicin—bone cancer	0.000213	0.00119	CcSEcCtD
Boceprevir—Pneumonia—Doxorubicin—bone cancer	0.000212	0.00119	CcSEcCtD
Boceprevir—Infestation—Doxorubicin—bone cancer	0.000211	0.00118	CcSEcCtD
Boceprevir—Infestation NOS—Doxorubicin—bone cancer	0.000211	0.00118	CcSEcCtD
Boceprevir—Visual impairment—Methotrexate—bone cancer	0.000211	0.00118	CcSEcCtD
Boceprevir—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000209	0.00117	CcSEcCtD
Boceprevir—Hypersensitivity—Cisplatin—bone cancer	0.000209	0.00117	CcSEcCtD
Boceprevir—Erythema multiforme—Methotrexate—bone cancer	0.000207	0.00116	CcSEcCtD
Boceprevir—Neuropathy peripheral—Doxorubicin—bone cancer	0.000207	0.00116	CcSEcCtD
Boceprevir—Stomatitis—Doxorubicin—bone cancer	0.000206	0.00115	CcSEcCtD
Boceprevir—Rhinitis—Epirubicin—bone cancer	0.000205	0.00115	CcSEcCtD
Boceprevir—Conjunctivitis—Doxorubicin—bone cancer	0.000205	0.00115	CcSEcCtD
Boceprevir—Urinary tract infection—Doxorubicin—bone cancer	0.000205	0.00115	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—bone cancer	0.000205	0.00114	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—bone cancer	0.000204	0.00114	CcSEcCtD
Boceprevir—Hypoaesthesia—Epirubicin—bone cancer	0.000204	0.00114	CcSEcCtD
Boceprevir—Asthenia—Cisplatin—bone cancer	0.000203	0.00114	CcSEcCtD
Boceprevir—Pharyngitis—Epirubicin—bone cancer	0.000203	0.00114	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—bone cancer	0.000203	0.00113	CcSEcCtD
Boceprevir—Urinary tract disorder—Epirubicin—bone cancer	0.000202	0.00113	CcSEcCtD
Boceprevir—Oedema peripheral—Epirubicin—bone cancer	0.000202	0.00113	CcSEcCtD
Boceprevir—Connective tissue disorder—Epirubicin—bone cancer	0.000201	0.00112	CcSEcCtD
Boceprevir—Urethral disorder—Epirubicin—bone cancer	0.000201	0.00112	CcSEcCtD
Boceprevir—Hepatobiliary disease—Doxorubicin—bone cancer	0.0002	0.00112	CcSEcCtD
Boceprevir—Epistaxis—Doxorubicin—bone cancer	0.000199	0.00111	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—bone cancer	0.000199	0.00111	CcSEcCtD
Boceprevir—Sinusitis—Doxorubicin—bone cancer	0.000198	0.00111	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—bone cancer	0.000198	0.0011	CcSEcCtD
Boceprevir—Visual impairment—Epirubicin—bone cancer	0.000197	0.0011	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—bone cancer	0.000197	0.0011	CcSEcCtD
Boceprevir—Agranulocytosis—Doxorubicin—bone cancer	0.000197	0.0011	CcSEcCtD
Boceprevir—CTSS—Extracellular matrix organization—MMP9—bone cancer	0.000197	0.00121	CbGpPWpGaD
Boceprevir—Chills—Methotrexate—bone cancer	0.000196	0.0011	CcSEcCtD
Boceprevir—CTSK—Immune System—ATF1—bone cancer	0.000196	0.00121	CbGpPWpGaD
Boceprevir—Diarrhoea—Cisplatin—bone cancer	0.000194	0.00108	CcSEcCtD
Boceprevir—Erythema multiforme—Epirubicin—bone cancer	0.000194	0.00108	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—bone cancer	0.000193	0.00108	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—KIT—bone cancer	0.000192	0.00118	CbGpPWpGaD
Boceprevir—Mental disorder—Methotrexate—bone cancer	0.000192	0.00107	CcSEcCtD
Boceprevir—CTSK—Immune System—IL3—bone cancer	0.000192	0.00118	CbGpPWpGaD
Boceprevir—Eye disorder—Epirubicin—bone cancer	0.000191	0.00107	CcSEcCtD
Boceprevir—Tinnitus—Epirubicin—bone cancer	0.000191	0.00107	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—bone cancer	0.000191	0.00106	CcSEcCtD
Boceprevir—Erythema—Methotrexate—bone cancer	0.000191	0.00106	CcSEcCtD
Boceprevir—Cardiac disorder—Epirubicin—bone cancer	0.00019	0.00106	CcSEcCtD
Boceprevir—Flushing—Epirubicin—bone cancer	0.00019	0.00106	CcSEcCtD
Boceprevir—Rhinitis—Doxorubicin—bone cancer	0.00019	0.00106	CcSEcCtD
Boceprevir—Hypoaesthesia—Doxorubicin—bone cancer	0.000189	0.00105	CcSEcCtD
Boceprevir—Pharyngitis—Doxorubicin—bone cancer	0.000188	0.00105	CcSEcCtD
Boceprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000187	0.00115	CbGpPWpGaD
Boceprevir—Urinary tract disorder—Doxorubicin—bone cancer	0.000187	0.00105	CcSEcCtD
Boceprevir—Oedema peripheral—Doxorubicin—bone cancer	0.000187	0.00104	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—bone cancer	0.000187	0.00104	CcSEcCtD
Boceprevir—Connective tissue disorder—Doxorubicin—bone cancer	0.000186	0.00104	CcSEcCtD
Boceprevir—Angiopathy—Epirubicin—bone cancer	0.000186	0.00104	CcSEcCtD
Boceprevir—Urethral disorder—Doxorubicin—bone cancer	0.000186	0.00104	CcSEcCtD
Boceprevir—Immune system disorder—Epirubicin—bone cancer	0.000185	0.00103	CcSEcCtD
Boceprevir—Mediastinal disorder—Epirubicin—bone cancer	0.000185	0.00103	CcSEcCtD
Boceprevir—Back pain—Methotrexate—bone cancer	0.000184	0.00103	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—KIT—bone cancer	0.000184	0.00114	CbGpPWpGaD
Boceprevir—Chills—Epirubicin—bone cancer	0.000184	0.00103	CcSEcCtD
Boceprevir—Arrhythmia—Epirubicin—bone cancer	0.000183	0.00102	CcSEcCtD
Boceprevir—Visual impairment—Doxorubicin—bone cancer	0.000183	0.00102	CcSEcCtD
Boceprevir—CTSV—Innate Immune System—MDM2—bone cancer	0.000182	0.00112	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—MDM2—bone cancer	0.000182	0.00112	CbGpPWpGaD
Boceprevir—Alopecia—Epirubicin—bone cancer	0.000181	0.00101	CcSEcCtD
Boceprevir—Vomiting—Cisplatin—bone cancer	0.00018	0.00101	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—bone cancer	0.00018	0.001	CcSEcCtD
Boceprevir—Mental disorder—Epirubicin—bone cancer	0.00018	0.001	CcSEcCtD
Boceprevir—Erythema multiforme—Doxorubicin—bone cancer	0.000179	0.001	CcSEcCtD
Boceprevir—Rash—Cisplatin—bone cancer	0.000179	0.000998	CcSEcCtD
Boceprevir—Dermatitis—Cisplatin—bone cancer	0.000179	0.000997	CcSEcCtD
Boceprevir—Malnutrition—Epirubicin—bone cancer	0.000178	0.000996	CcSEcCtD
Boceprevir—Erythema—Epirubicin—bone cancer	0.000178	0.000996	CcSEcCtD
Boceprevir—Eye disorder—Doxorubicin—bone cancer	0.000177	0.000989	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—bone cancer	0.000177	0.000987	CcSEcCtD
Boceprevir—Tinnitus—Doxorubicin—bone cancer	0.000177	0.000987	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—bone cancer	0.000176	0.000983	CcSEcCtD
Boceprevir—Cardiac disorder—Doxorubicin—bone cancer	0.000176	0.000982	CcSEcCtD
Boceprevir—Flushing—Doxorubicin—bone cancer	0.000176	0.000982	CcSEcCtD
Boceprevir—Flatulence—Epirubicin—bone cancer	0.000176	0.000981	CcSEcCtD
Boceprevir—CTSV—Adaptive Immune System—MDM2—bone cancer	0.000175	0.00108	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—MDM2—bone cancer	0.000175	0.00108	CbGpPWpGaD
Boceprevir—Dysgeusia—Epirubicin—bone cancer	0.000175	0.000975	CcSEcCtD
Boceprevir—Back pain—Epirubicin—bone cancer	0.000173	0.000963	CcSEcCtD
Boceprevir—Angiopathy—Doxorubicin—bone cancer	0.000172	0.00096	CcSEcCtD
Boceprevir—Malaise—Methotrexate—bone cancer	0.000172	0.00096	CcSEcCtD
Boceprevir—Muscle spasms—Epirubicin—bone cancer	0.000171	0.000957	CcSEcCtD
Boceprevir—Immune system disorder—Doxorubicin—bone cancer	0.000171	0.000956	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—bone cancer	0.000171	0.000956	CcSEcCtD
Boceprevir—Mediastinal disorder—Doxorubicin—bone cancer	0.000171	0.000954	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—bone cancer	0.000171	0.000952	CcSEcCtD
Boceprevir—Chills—Doxorubicin—bone cancer	0.00017	0.00095	CcSEcCtD
Boceprevir—Arrhythmia—Doxorubicin—bone cancer	0.000169	0.000945	CcSEcCtD
Boceprevir—Nausea—Cisplatin—bone cancer	0.000168	0.00094	CcSEcCtD
Boceprevir—Vision blurred—Epirubicin—bone cancer	0.000168	0.000938	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—SMO—bone cancer	0.000168	0.00103	CbGpPWpGaD
Boceprevir—Alopecia—Doxorubicin—bone cancer	0.000168	0.000935	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—MMP2—bone cancer	0.000167	0.00103	CbGpPWpGaD
Boceprevir—Cough—Methotrexate—bone cancer	0.000166	0.000928	CcSEcCtD
Boceprevir—Mental disorder—Doxorubicin—bone cancer	0.000166	0.000927	CcSEcCtD
Boceprevir—Ill-defined disorder—Epirubicin—bone cancer	0.000166	0.000924	CcSEcCtD
Boceprevir—Malnutrition—Doxorubicin—bone cancer	0.000165	0.000921	CcSEcCtD
Boceprevir—Erythema—Doxorubicin—bone cancer	0.000165	0.000921	CcSEcCtD
Boceprevir—Anaemia—Epirubicin—bone cancer	0.000165	0.00092	CcSEcCtD
Boceprevir—Agitation—Epirubicin—bone cancer	0.000164	0.000915	CcSEcCtD
Boceprevir—Flatulence—Doxorubicin—bone cancer	0.000163	0.000908	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—bone cancer	0.000162	0.000906	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—bone cancer	0.000162	0.000906	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—bone cancer	0.000162	0.000906	CcSEcCtD
Boceprevir—CTSS—Immune System—ATF1—bone cancer	0.000162	0.000997	CbGpPWpGaD
Boceprevir—Dysgeusia—Doxorubicin—bone cancer	0.000162	0.000902	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000161	0.0009	CcSEcCtD
Boceprevir—Malaise—Epirubicin—bone cancer	0.000161	0.000898	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—bone cancer	0.00016	0.000895	CcSEcCtD
Boceprevir—Vertigo—Epirubicin—bone cancer	0.00016	0.000895	CcSEcCtD
Boceprevir—Syncope—Epirubicin—bone cancer	0.00016	0.000893	CcSEcCtD
Boceprevir—Leukopenia—Epirubicin—bone cancer	0.00016	0.000891	CcSEcCtD
Boceprevir—Back pain—Doxorubicin—bone cancer	0.00016	0.000891	CcSEcCtD
Boceprevir—Muscle spasms—Doxorubicin—bone cancer	0.000159	0.000886	CcSEcCtD
Boceprevir—CTSV—Innate Immune System—JUN—bone cancer	0.000159	0.000977	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—JUN—bone cancer	0.000159	0.000977	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—KIT—bone cancer	0.000158	0.000974	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL3—bone cancer	0.000158	0.000972	CbGpPWpGaD
Boceprevir—Palpitations—Epirubicin—bone cancer	0.000158	0.00088	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—bone cancer	0.000157	0.000876	CcSEcCtD
Boceprevir—Loss of consciousness—Epirubicin—bone cancer	0.000157	0.000875	CcSEcCtD
Boceprevir—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000156	0.00096	CbGpPWpGaD
Boceprevir—Cough—Epirubicin—bone cancer	0.000156	0.000869	CcSEcCtD
Boceprevir—Vision blurred—Doxorubicin—bone cancer	0.000156	0.000868	CcSEcCtD
Boceprevir—Infection—Methotrexate—bone cancer	0.000155	0.000863	CcSEcCtD
Boceprevir—Hypertension—Epirubicin—bone cancer	0.000154	0.00086	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000154	0.000947	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000153	0.000945	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—GNA11—bone cancer	0.000153	0.000944	CbGpPWpGaD
Boceprevir—Ill-defined disorder—Doxorubicin—bone cancer	0.000153	0.000855	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—bone cancer	0.000153	0.000852	CcSEcCtD
Boceprevir—Anaemia—Doxorubicin—bone cancer	0.000153	0.000852	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—bone cancer	0.000152	0.00085	CcSEcCtD
Boceprevir—Arthralgia—Epirubicin—bone cancer	0.000152	0.000848	CcSEcCtD
Boceprevir—Myalgia—Epirubicin—bone cancer	0.000152	0.000848	CcSEcCtD
Boceprevir—Chest pain—Epirubicin—bone cancer	0.000152	0.000848	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—KIT—bone cancer	0.000152	0.000935	CbGpPWpGaD
Boceprevir—Agitation—Doxorubicin—bone cancer	0.000152	0.000847	CcSEcCtD
Boceprevir—Anxiety—Epirubicin—bone cancer	0.000151	0.000845	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—MDM2—bone cancer	0.000151	0.000931	CbGpPWpGaD
Boceprevir—Skin disorder—Methotrexate—bone cancer	0.000151	0.000843	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000151	0.000842	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—bone cancer	0.00015	0.000839	CcSEcCtD
Boceprevir—Discomfort—Epirubicin—bone cancer	0.00015	0.000838	CcSEcCtD
Boceprevir—Malaise—Doxorubicin—bone cancer	0.000149	0.000831	CcSEcCtD
Boceprevir—Dry mouth—Epirubicin—bone cancer	0.000149	0.000829	CcSEcCtD
Boceprevir—Vertigo—Doxorubicin—bone cancer	0.000148	0.000828	CcSEcCtD
Boceprevir—Syncope—Doxorubicin—bone cancer	0.000148	0.000826	CcSEcCtD
Boceprevir—Leukopenia—Doxorubicin—bone cancer	0.000148	0.000825	CcSEcCtD
Boceprevir—Confusional state—Epirubicin—bone cancer	0.000147	0.000819	CcSEcCtD
Boceprevir—Palpitations—Doxorubicin—bone cancer	0.000146	0.000814	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—bone cancer	0.000145	0.000811	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—MDM2—bone cancer	0.000145	0.000894	CbGpPWpGaD
Boceprevir—Loss of consciousness—Doxorubicin—bone cancer	0.000145	0.00081	CcSEcCtD
Boceprevir—Infection—Epirubicin—bone cancer	0.000145	0.000807	CcSEcCtD
Boceprevir—Cough—Doxorubicin—bone cancer	0.000144	0.000804	CcSEcCtD
Boceprevir—Shock—Epirubicin—bone cancer	0.000143	0.0008	CcSEcCtD
Boceprevir—Nervous system disorder—Epirubicin—bone cancer	0.000143	0.000797	CcSEcCtD
Boceprevir—Thrombocytopenia—Epirubicin—bone cancer	0.000143	0.000796	CcSEcCtD
Boceprevir—Hypertension—Doxorubicin—bone cancer	0.000142	0.000795	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—ATF1—bone cancer	0.000142	0.000878	CbGpPWpGaD
Boceprevir—Tachycardia—Epirubicin—bone cancer	0.000142	0.000793	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000142	0.000791	CcSEcCtD
Boceprevir—Skin disorder—Epirubicin—bone cancer	0.000141	0.000789	CcSEcCtD
Boceprevir—Hyperhidrosis—Epirubicin—bone cancer	0.000141	0.000786	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—bone cancer	0.000141	0.000785	CcSEcCtD
Boceprevir—Myalgia—Doxorubicin—bone cancer	0.000141	0.000784	CcSEcCtD
Boceprevir—Arthralgia—Doxorubicin—bone cancer	0.000141	0.000784	CcSEcCtD
Boceprevir—Chest pain—Doxorubicin—bone cancer	0.000141	0.000784	CcSEcCtD
Boceprevir—Anxiety—Doxorubicin—bone cancer	0.00014	0.000782	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—bone cancer	0.00014	0.00078	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00014	0.000779	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—IL3—bone cancer	0.000139	0.000856	CbGpPWpGaD
Boceprevir—Discomfort—Doxorubicin—bone cancer	0.000139	0.000775	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—bone cancer	0.000139	0.000774	CcSEcCtD
Boceprevir—Dry mouth—Doxorubicin—bone cancer	0.000137	0.000767	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—bone cancer	0.000137	0.000764	CcSEcCtD
Boceprevir—Hypotension—Epirubicin—bone cancer	0.000136	0.000759	CcSEcCtD
Boceprevir—Confusional state—Doxorubicin—bone cancer	0.000136	0.000758	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—bone cancer	0.000135	0.000755	CcSEcCtD
Boceprevir—CTSL—Immune System—KIT—bone cancer	0.000135	0.000831	CbGpPWpGaD
Boceprevir—CTSV—Immune System—KIT—bone cancer	0.000135	0.000831	CbGpPWpGaD
Boceprevir—Gastrointestinal disorder—Methotrexate—bone cancer	0.000134	0.00075	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—bone cancer	0.000134	0.000749	CcSEcCtD
Boceprevir—Infection—Doxorubicin—bone cancer	0.000134	0.000747	CcSEcCtD
Boceprevir—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000133	0.000821	CbGpPWpGaD
Boceprevir—Pain—Methotrexate—bone cancer	0.000133	0.000743	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000133	0.00074	CcSEcCtD
Boceprevir—Shock—Doxorubicin—bone cancer	0.000133	0.00074	CcSEcCtD
Boceprevir—Nervous system disorder—Doxorubicin—bone cancer	0.000132	0.000737	CcSEcCtD
Boceprevir—Thrombocytopenia—Doxorubicin—bone cancer	0.000132	0.000736	CcSEcCtD
Boceprevir—Insomnia—Epirubicin—bone cancer	0.000132	0.000735	CcSEcCtD
Boceprevir—Tachycardia—Doxorubicin—bone cancer	0.000131	0.000734	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000131	0.00081	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—JUN—bone cancer	0.000131	0.00081	CbGpPWpGaD
Boceprevir—Skin disorder—Doxorubicin—bone cancer	0.000131	0.00073	CcSEcCtD
Boceprevir—Paraesthesia—Epirubicin—bone cancer	0.000131	0.00073	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00013	0.000803	CbGpPWpGaD
Boceprevir—Hyperhidrosis—Doxorubicin—bone cancer	0.00013	0.000727	CcSEcCtD
Boceprevir—Dyspnoea—Epirubicin—bone cancer	0.00013	0.000725	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—bone cancer	0.000128	0.000716	CcSEcCtD
Boceprevir—Dyspepsia—Epirubicin—bone cancer	0.000128	0.000715	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—bone cancer	0.000127	0.00071	CcSEcCtD
Boceprevir—Decreased appetite—Epirubicin—bone cancer	0.000127	0.000706	CcSEcCtD
Boceprevir—Hypotension—Doxorubicin—bone cancer	0.000126	0.000703	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Epirubicin—bone cancer	0.000126	0.000702	CcSEcCtD
Boceprevir—Fatigue—Epirubicin—bone cancer	0.000126	0.000701	CcSEcCtD
Boceprevir—CTSL—Innate Immune System—EGFR—bone cancer	0.000125	0.000768	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—EGFR—bone cancer	0.000125	0.000768	CbGpPWpGaD
Boceprevir—Constipation—Epirubicin—bone cancer	0.000124	0.000695	CcSEcCtD
Boceprevir—Pain—Epirubicin—bone cancer	0.000124	0.000695	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—MDM2—bone cancer	0.000124	0.000767	CbGpPWpGaD
Boceprevir—Urticaria—Methotrexate—bone cancer	0.000124	0.00069	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—bone cancer	0.000123	0.000686	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—bone cancer	0.000123	0.000686	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000123	0.000685	CcSEcCtD
Boceprevir—Insomnia—Doxorubicin—bone cancer	0.000122	0.00068	CcSEcCtD
Boceprevir—Paraesthesia—Doxorubicin—bone cancer	0.000121	0.000675	CcSEcCtD
Boceprevir—Dyspnoea—Doxorubicin—bone cancer	0.00012	0.00067	CcSEcCtD
Boceprevir—Feeling abnormal—Epirubicin—bone cancer	0.00012	0.00067	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—EGFR—bone cancer	0.00012	0.000738	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—EGFR—bone cancer	0.00012	0.000738	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—MDM2—bone cancer	0.00012	0.000736	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Epirubicin—bone cancer	0.000119	0.000665	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—TGFBR2—bone cancer	0.000119	0.000732	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000119	0.000731	CbGpPWpGaD
Boceprevir—Dyspepsia—Doxorubicin—bone cancer	0.000119	0.000662	CcSEcCtD
Boceprevir—Decreased appetite—Doxorubicin—bone cancer	0.000117	0.000654	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000116	0.000649	CcSEcCtD
Boceprevir—Fatigue—Doxorubicin—bone cancer	0.000116	0.000648	CcSEcCtD
Boceprevir—Urticaria—Epirubicin—bone cancer	0.000116	0.000646	CcSEcCtD
Boceprevir—Constipation—Doxorubicin—bone cancer	0.000115	0.000643	CcSEcCtD
Boceprevir—Pain—Doxorubicin—bone cancer	0.000115	0.000643	CcSEcCtD
Boceprevir—Abdominal pain—Epirubicin—bone cancer	0.000115	0.000642	CcSEcCtD
Boceprevir—Body temperature increased—Epirubicin—bone cancer	0.000115	0.000642	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—bone cancer	0.000115	0.00064	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—IGF1R—bone cancer	0.000112	0.000689	CbGpPWpGaD
Boceprevir—CTSK—Immune System—KIT—bone cancer	0.000112	0.000689	CbGpPWpGaD
Boceprevir—Asthenia—Methotrexate—bone cancer	0.000112	0.000623	CcSEcCtD
Boceprevir—Feeling abnormal—Doxorubicin—bone cancer	0.000111	0.00062	CcSEcCtD
Boceprevir—Gastrointestinal pain—Doxorubicin—bone cancer	0.00011	0.000615	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—bone cancer	0.00011	0.000614	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—JUN—bone cancer	0.000108	0.000667	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000108	0.000666	CbGpPWpGaD
Boceprevir—Hypersensitivity—Epirubicin—bone cancer	0.000107	0.000599	CcSEcCtD
Boceprevir—Urticaria—Doxorubicin—bone cancer	0.000107	0.000597	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000107	0.000657	CbGpPWpGaD
Boceprevir—Abdominal pain—Doxorubicin—bone cancer	0.000106	0.000594	CcSEcCtD
Boceprevir—Body temperature increased—Doxorubicin—bone cancer	0.000106	0.000594	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—bone cancer	0.000106	0.000594	CcSEcCtD
Boceprevir—CTSL—Immune System—MDM2—bone cancer	0.000106	0.000655	CbGpPWpGaD
Boceprevir—CTSV—Immune System—MDM2—bone cancer	0.000106	0.000655	CbGpPWpGaD
Boceprevir—Asthenia—Epirubicin—bone cancer	0.000104	0.000583	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—EGFR—bone cancer	0.000103	0.000636	CbGpPWpGaD
Boceprevir—Pruritus—Epirubicin—bone cancer	0.000103	0.000575	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—bone cancer	0.000103	0.000574	CcSEcCtD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000101	0.000623	CbGpPWpGaD
Boceprevir—Diarrhoea—Epirubicin—bone cancer	9.96e-05	0.000556	CcSEcCtD
Boceprevir—Hypersensitivity—Doxorubicin—bone cancer	9.92e-05	0.000554	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—EGFR—bone cancer	9.92e-05	0.000611	CbGpPWpGaD
Boceprevir—Vomiting—Methotrexate—bone cancer	9.89e-05	0.000552	CcSEcCtD
Boceprevir—Rash—Methotrexate—bone cancer	9.81e-05	0.000548	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—bone cancer	9.8e-05	0.000547	CcSEcCtD
Boceprevir—Headache—Methotrexate—bone cancer	9.75e-05	0.000544	CcSEcCtD
Boceprevir—Asthenia—Doxorubicin—bone cancer	9.66e-05	0.000539	CcSEcCtD
Boceprevir—Dizziness—Epirubicin—bone cancer	9.63e-05	0.000537	CcSEcCtD
Boceprevir—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.56e-05	0.000589	CbGpPWpGaD
Boceprevir—Pruritus—Doxorubicin—bone cancer	9.53e-05	0.000532	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—NDUFA12—bone cancer	9.34e-05	0.000575	CbGpPWpGaD
Boceprevir—Vomiting—Epirubicin—bone cancer	9.26e-05	0.000517	CcSEcCtD
Boceprevir—Nausea—Methotrexate—bone cancer	9.24e-05	0.000516	CcSEcCtD
Boceprevir—CTSL—Immune System—JUN—bone cancer	9.23e-05	0.000569	CbGpPWpGaD
Boceprevir—CTSV—Immune System—JUN—bone cancer	9.23e-05	0.000569	CbGpPWpGaD
Boceprevir—Diarrhoea—Doxorubicin—bone cancer	9.22e-05	0.000514	CcSEcCtD
Boceprevir—CTSS—Immune System—KIT—bone cancer	9.2e-05	0.000567	CbGpPWpGaD
Boceprevir—Rash—Epirubicin—bone cancer	9.18e-05	0.000512	CcSEcCtD
Boceprevir—Dermatitis—Epirubicin—bone cancer	9.17e-05	0.000512	CcSEcCtD
Boceprevir—Headache—Epirubicin—bone cancer	9.12e-05	0.000509	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.03e-05	0.000557	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.01e-05	0.000555	CbGpPWpGaD
Boceprevir—Dizziness—Doxorubicin—bone cancer	8.91e-05	0.000497	CcSEcCtD
Boceprevir—CTSK—Immune System—MDM2—bone cancer	8.8e-05	0.000542	CbGpPWpGaD
Boceprevir—Nausea—Epirubicin—bone cancer	8.65e-05	0.000483	CcSEcCtD
Boceprevir—Vomiting—Doxorubicin—bone cancer	8.56e-05	0.000478	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—EGFR—bone cancer	8.5e-05	0.000524	CbGpPWpGaD
Boceprevir—Rash—Doxorubicin—bone cancer	8.49e-05	0.000474	CcSEcCtD
Boceprevir—Dermatitis—Doxorubicin—bone cancer	8.49e-05	0.000474	CcSEcCtD
Boceprevir—Headache—Doxorubicin—bone cancer	8.44e-05	0.000471	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—EGFR—bone cancer	8.17e-05	0.000503	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—KIT—bone cancer	8.11e-05	0.0005	CbGpPWpGaD
Boceprevir—Nausea—Doxorubicin—bone cancer	8e-05	0.000447	CcSEcCtD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.78e-05	0.000479	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NT5C3A—bone cancer	7.74e-05	0.000477	CbGpPWpGaD
Boceprevir—CTSK—Immune System—JUN—bone cancer	7.65e-05	0.000472	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—BRAF—bone cancer	7.62e-05	0.00047	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EGFR—bone cancer	7.26e-05	0.000447	CbGpPWpGaD
Boceprevir—CTSL—Immune System—EGFR—bone cancer	7.26e-05	0.000447	CbGpPWpGaD
Boceprevir—CTSS—Immune System—MDM2—bone cancer	7.25e-05	0.000447	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NDUFA12—bone cancer	7.04e-05	0.000434	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.7e-05	0.000413	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MDM2—bone cancer	6.39e-05	0.000393	CbGpPWpGaD
Boceprevir—CTSS—Immune System—JUN—bone cancer	6.3e-05	0.000388	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.19e-05	0.000382	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.11e-05	0.000376	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EGFR—bone cancer	6.02e-05	0.000371	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NT5C3A—bone cancer	5.84e-05	0.00036	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—JUN—bone cancer	5.55e-05	0.000342	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MMP9—bone cancer	5.4e-05	0.000333	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.97e-05	0.000306	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EGFR—bone cancer	4.95e-05	0.000305	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.79e-05	0.000295	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EGFR—bone cancer	4.36e-05	0.000269	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NDUFA12—bone cancer	4.34e-05	0.000267	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.32e-05	0.000266	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—bone cancer	3.66e-05	0.000226	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NT5C3A—bone cancer	3.6e-05	0.000222	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.39e-05	0.000209	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ENO2—bone cancer	3.39e-05	0.000209	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—DHFR—bone cancer	3.14e-05	0.000194	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GNA11—bone cancer	2.94e-05	0.000181	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.85e-05	0.000176	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP3A4—bone cancer	2.66e-05	0.000164	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ENO2—bone cancer	2.56e-05	0.000158	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—DHFR—bone cancer	2.37e-05	0.000146	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTP1—bone cancer	2.28e-05	0.00014	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GNA11—bone cancer	2.22e-05	0.000137	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP3A4—bone cancer	2.01e-05	0.000124	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTP1—bone cancer	1.72e-05	0.000106	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ENO2—bone cancer	1.58e-05	9.71e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—DHFR—bone cancer	1.46e-05	9.01e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GNA11—bone cancer	1.37e-05	8.42e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTGS2—bone cancer	1.18e-05	7.27e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTP1—bone cancer	1.06e-05	6.53e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTGS2—bone cancer	8.91e-06	5.49e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTGS2—bone cancer	5.49e-06	3.38e-05	CbGpPWpGaD
